For instance, CF people harboring F508del- or N1303K-CFTR variants were reported to have variable responses to modulators in vivo and in vitro, demonstrating the importance of using the predictive power of patient-derived rectal organoids for applying the personalized medicine approach in order to optimize the treatment in CF patients. This evidence concerns the gene CFTR and cystic fibrosis.